Now Booking Free 30-minute strategy call For clinic founders and owners See if you qualify
Regenerative Health Clinic Compliance: The 5 Things That Actually Shut Clinics Down

Regenerative Health Clinic Compliance: The 5 Things That Actually Shut Clinics Down

Regenerative Health Clinic Compliance: The 5 Things That Actually Shut Clinics DownNova S.
Published on: 01/10/2026

The five compliance failures that actually shut down regenerative health clinics — ownership structure, unapproved biologics, compounding sourcing, marketing claims, and advertising platform enforcement.

regenerative health clinic complianceregenerative clinic legal requirementswhat shuts down a clinicclinic FDA enforcementmedical clinic compliance riskregenerative medicine clinic regulationscorporate practice of medicine clinicFDA unapproved biologics clinic503A 503B sourcing complianceFTC health claims clinichealthcare advertising policy
Read more
Built by operators. Our team has launched hundreds of clinics.

A regenerative health clinic consulting firm. We help entrepreneurs open Regenerative Health, Longevity, and MedSpa clinics; our team has launched and optimized hundreds. No medical background is required to own the business; an independent, state-licensed Medical Director directs all clinical care.

Clinics Supported Nationwide
Serving Entrepreneurs Across All 50 States
No Medical Background Required
Independent Medical Director Leads Care
One-Time Consulting Fee. No Royalties
60-Day Target Launch Window*

© 2026 Altos Consulting Group. All rights reserved.

Altos Consulting Group is a business consulting and advisory firm. ACG is not a medical practice and does not provide medical care, diagnose, prescribe, dispense, or manufacture any drug, biologic, device, or therapy. At every clinic we support, all clinical and treatment decisions are made by independent, state-licensed medical providers who own and direct patient care, consistent with applicable Corporate Practice of Medicine laws. Regenerative and cash-pay therapies, including PRP, peptides, GLP-1 medications, and exosome or cellular products, are subject to federal and state regulation, and not all products or uses are FDA-approved or cleared; the FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease. Clinic owners are responsible for ensuring their products, therapies, and marketing comply with all FDA, FTC, state medical board, and state advertising requirements. Any results, revenue figures, or timelines shown are illustrative, reflect specific clients under specific conditions, are not typical, and are not guarantees of income or success; individual outcomes vary by market, location, capital, regulatory conditions, and operator execution. ACG partners with vetted lending providers to help clients access capital and does not act as a lender. The "60-day launch window" is a target, not a guarantee, and varies by state, market, and regulatory conditions. FTC Disclaimer: results described in testimonials and case studies are not typical, and individual results will vary. © 2026 Altos Consulting Group.